Observational studyTremor and other hyperkinetic movements (New York, N.Y.)2026
Effects of Focal Low-Energy Extracorporeal Shock Wave Treatment (ESWT) as an Add-On to Botulinum Toxin (BoNT) Injection on Pisa Syndrome in Parkinson's Disease.
Observational study in Tremor and other hyperkinetic movements (New York, N.Y.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Pisa syndrome (PS) is a reversible lateral trunk deviation that arises as a complication in a subset of patients with Parkinson's disease (PD). Effective therapeutic options remain limited, and standardized protocols are lacking. Extracorporeal shock wave therapy (ESWT), an intervention with emerging antidystonic and antispastic properties, has shown promising effects on muscle spasms and dystonia. We aimed at evaluating the feasibility, safety, and preliminary therapeutic effects of ESWT combined with botulinum toxin (BoNT) for reducing paraspinal muscle tone and pain in patients with PS. Methods: This crossover observational study analyzed data collected in routine clinical practice in patients with PS undergoing focused ESWT applied to ipsilateral paraspinal muscles immediately prior to BoNT injections.Fifteen patients were enrolled, and eleven completed the full protocol, which included ESWT+BoNT and sham ESWT+BoNT administered according to clinical scheduling, with a washout phase lasting no less than 3 months between treatment conditions. Clinical evaluations were performed at baseline, immediately post-treatment, and at 1 and 3 months post-treatment. Outcome measures included lateral trunk flexion angle, UPDRS part III scores, pain intensity ratings, quality of life assessments, and surface electromyography (sEMG) of axial muscles. Results: The primary finding was a significant immediate reduction in lateral trunk flexion following active ESWT compared with sham (p = 0.038). However, no sustained effects were observed at 1 or 3 month post-treatment for posture, motor severity, pain, or patient-reported outcomes. sEMG analysis did not demonstrate significant modifications in muscle activation patterns. ESWT was well tolerated, only mild, transient discomfort was reported, and no systemic adverse events occurred. Discussion: These findings provide evidence that focused ESWT may acutely reduce lateral trunk flexion in PS when used as an adjunct to BoNT. Larger studies are warranted to better define its therapeutic potential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.